Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs Sells 7,035 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kymera Therapeutics Stock Down 3.8 %

NASDAQ KYMR opened at $30.17 on Tuesday. Kymera Therapeutics, Inc. has a twelve month low of $29.16 and a twelve month high of $53.27. The business has a 50-day moving average price of $38.81 and a 200-day moving average price of $43.66. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -12.89 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KYMR. Mirae Asset Global Investments Co. Ltd. increased its holdings in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Kymera Therapeutics by 30.0% during the third quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company’s stock valued at $1,908,000 after purchasing an additional 9,292 shares in the last quarter. Natixis Advisors LLC bought a new stake in shares of Kymera Therapeutics in the third quarter worth about $681,000. Thrivent Financial for Lutherans purchased a new stake in shares of Kymera Therapeutics in the third quarter worth about $313,000. Finally, Jennison Associates LLC lifted its position in shares of Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on KYMR. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Morgan Stanley increased their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. UBS Group dropped their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, BMO Capital Markets started coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $56.69.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.